Thu, Oct 2, 2014, 1:39 AM EDT - U.S. Markets open in 7 hrs 51 mins


% | $
Quotes you view appear here for quick access.

Organovo Holdings, Inc. Message Board

ogewen 3 posts  |  Last Activity: Sep 24, 2014 12:25 PM Member since: Apr 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Litlle known use for Brilacidin

    by ogewen Sep 24, 2014 11:05 AM
    ogewen ogewen Sep 24, 2014 12:25 PM Flag

    I'm in total agreement. Thanks for your input. All the best. Ogewen

  • Over the past 20 years of my medical practice treating ocular diseases I have seen antibiotic after antibiotic fail to continue to cure various diseases. Why? Because the offending organisms have become drug resistant. Conjunctivitis (pink eye) is the most contagious disease known to man. Although they mostly are self limiting in most countries even without drug therapy they can be and are diseases that cause permanent blindness in third world countries. This occurs predominantly as a result of secondary infections. The drug resistance of the latest drugs, i.e. Vigamox, Besivance, Zymar creates problems for the practioner. Often times my own patients will not complete the course of treatment I prescribed because the offending eye feels better and looks better after a few days of usage. Therein lies the problem. The so called "bug" will not be truly destroyed and then mutates into a different microbe. This occurs now with other infectious diseases systemically and topically. I often will refrain from over prescribing to prevent this epidemic problem of drug resistant bacteria. This, however, forces me to have the patient return more frequently to observe the eye to avoid potentially more serious consequences. Multiply this by the millions of time in this country alone and the cost to consumers/insurances are mind boggling. Moreover, when patients are contagious and not working, possibly for 7-10 days, the economic cost to the patient and employer are staggering. Brilacidn, in just this usage alone, could eliminate the need for patient compliance due to their single dosage and defensin-mimetic properties. Just for this one application of Brilacidn the value to Pharma would be in the Billions of dollars in the US. If you extrapolate that to other diseases and world wide usage the profitability of Brilacidn and CTIX boggles the imagination. Intelligent discussions and opinions are welcome. All the best. Ogewen.

  • Haven't been here in a while, but I respect your acumen and expertise, Robbie and agree with "patience". I mostly agree with you. My concern now and has been the inordinate amount of acquisitions in the past 18 months, accretive income is not organic and gives the perception that DDD can't or won't grow organically. Perception is reality and the analysts are now mostly neutral to negative and downplaying DDD future. Avi needs to step up and clarify DDD's direction. IMHO he's juggling to many balls in the air. He needs to stop and catch some of them and develop profitable products. I believe the time frame is 12 months when acquisition profits are incorporated and become organic, but I could be mistaken in timing. If the myriad of acquisitions are, indeed, profitable we will see increase in PPS and hopefully earnings will beat the street in next two qtrs. IMHO DDD's PR has been abysmal of late and they need to step up to the plate and give better guidance and clarity for both near term and long term vision of profitability. I would welcome intelligent discourse both pro and con my position. All the best, Ogewen

6.02-0.35(-5.49%)Oct 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.